News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Marlise R. Luskin: Severe neutropenia is associated with blinatumomab
Photo from Marlise R. Luskin/X
Oct 1, 2024, 11:39

Marlise R. Luskin: Severe neutropenia is associated with blinatumomab

Marlise R. Luskin, leukemia specialist at Dana-Farber Cancer Institute, posted on X:

“Severe neutropenia is associated with blinatumomab! Blina is not considered myelosuppressive, but have observed severe neutropenia. We studied 95 pts receiving blina in CR at Dana-Farber Cancer Institute 41% gr≥3 neutropenia, 13% ANC <100, no serious infections, not necessarily recurrent!”

Source: Marlise R. Luskin/X

blinatumomab cancer Dana-Farber Cancer Institute Marlise R. Luskin OncoDaily Oncology
Special Coverage
Blog
Dec 19, 2024, 14:01
The ESMO Asia Congress 2024 was a milestone in advancing oncology research and treatment in Asia-Pacific
Blog
Dec 19, 2024, 13:55
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Hormone Receptor–Positive Breast cancer
Insight
Dec 19, 2024, 13:48
Myeloma Paper of the Day, December 19th, suggested by Robert Orlowski
Blog
Dec 19, 2024, 13:35
OncoInfluencers to Follow on Social Media: Catharine Young
Science
Dec 19, 2024, 13:02
Razelle Kurzrock: Tumor size correlates linearly with outcome after IO in rare cancer
Science
Dec 19, 2024, 12:58
TIGIT and PD-L1 co-blockade promotes clonal expansion of antitumor T cells by Enchancing Co-stimulation
Science
Dec 19, 2024, 12:55
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC
Science
Dec 19, 2024, 12:39
Mayo Clinic Genetic Risk models in Venetoclax-HMA treated AML
Science
Dec 19, 2024, 12:33
Sacituzumab govitecan vs platinum-based chemotherapy for Urothelial Carcinoma - ESMO
Science
Dec 19, 2024, 12:23
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
Blog
Dec 19, 2024, 12:20
9th Annual ELLOK Conference: From Theory to Practice
Insight
Dec 19, 2024, 12:01
Remon Jordi Discusses Advances in Thoracic Oncology at ESMO Asia 2024